Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Earnings for Acorda Therapeutics, Inc. (ACOR)
Earnings in 2023 (TTM): $-296,021,000
According to Acorda Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-296,021,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Acorda Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-296,021,000 | $-252,854,000 |
| 2022 | $-35,247,000 | $-65,916,000 |
| 2021 | $-109,074,000 | $-103,954,000 |
| 2020 | $-107,667,000 | $-99,594,000 |
| 2019 | $-274,247,000 | $-272,965,000 |
| 2018 | $20.42 M | $33.68 M |
| 2017 | $-251,885,000 | $-223,359,000 |
| 2016 | $-42,268,000 | $-34,618,000 |
| 2015 | $19.37 M | $11.06 M |
| 2014 | $28.01 M | $17.67 M |
| 2013 | $28.86 M | $16.44 M |
| 2012 | $24.27 M | $154.96 M |
| 2011 | $32.02 M | $30.61 M |
| 2010 | $-11,770,000 | $-11,769,000 |
| 2009 | $-83,940,242 | $-83,941,000 |
| 2008 | $-73,431,269 | $-74,340,640 |
| 2007 | $-39,396,598 | $-37,974,467 |
| 2006 | $-23,391,488 | $-24,019,372 |
| 2005 | $-34,408,489 | $-35,530,247 |
| 2004 | $-44,764,463 | $-44,740,764 |
| 2003 | $-63,115,000 | $-62,446,000 |